OTCMKTS:NTII

Neurobiological Technologies (NTII) Stock Price, News & Analysis

About Neurobiological Technologies Stock (OTCMKTS:NTII)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Neurobiological Technologies, Inc. was a biotechnology company focused on developing therapies for neurological and neurovascular disorders. The company’s research and development activities historically centered on treatments for conditions such as acute ischemic stroke, brain tumors and related neurological complications.

Its most prominent investigational product was Viprinex, an intravenous formulation of ancrod, an anticoagulant enzyme derived from Malayan pit viper venom that was studied as a potential treatment for acute ischemic stroke. Neurobiological Technologies also pursued additional neuroscience programs, including therapies intended to address brain edema and other neurological conditions.

The company’s activities were primarily associated with drug development rather than commercialized products, and its programs were advanced through clinical trials and licensing relationships. Publicly available information about its later operations, current business activities and leadership is limited.

AI Generated. May Contain Errors.

Receive NTII Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurobiological Technologies and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NTII Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Company Calendar

Today
11/18/2026
Fiscal Year End
6/30/2027

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:NTII
CIK
N/A
Employees
4
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (OTCMKTS:NTII) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners